Trevi Therapeutics (TRVI) Return on Invested Capital (2021 - 2024)

Trevi Therapeutics' Return on Invested Capital history runs 4 years deep, the most recent figure standing at 3.15% for Q3 2024.

• On a quarterly basis, Return on Invested Capital fell 313.0% year-over-year to 3.15% in Q3 2024; TTM through Sep 2024 was 3.15%, a 313.0% decrease from a year earlier, with the FY2023 full-year figure at 0.09%, down 5.0% from the prior year.
• Return on Invested Capital eased to 3.15% in Q3 2024 per TRVI's latest filing, from 2.82% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q1 2023 and bottomed at 3.15% in Q3 2024.
• The 4-year median for Return on Invested Capital is 0.03% (2022), against an average of 0.46%.
• Across the five-year window, Return on Invested Capital gained 18 bps in 2022 and sank 313 bps in 2024, its largest moves.
• Year by year, Return on Invested Capital stood at 0.03% in 2021, then jumped by 67 bps to 0.01% in 2022, then sank by 181 bps to 0.03% in 2023, then tumbled by 10177 bps to 3.15% in 2024.
• Per Business Quant, the three latest TRVI Return on Invested Capital figures stand at 3.15% (Q3 2024), 2.82% (Q2 2024), and 0.1% (Q1 2024).